Compare
Harrow, Inc. vs Arvinas, Inc. vs Xeris Biopharma Holdings, Inc. vs Evolus, Inc.
| Latest fiscal year | Harrow, Inc. HROW | Arvinas, Inc. ARVN | Xeris Biopharma Holdings, Inc. XERS | Evolus, Inc. EOLS |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $272.30M | $262.60M | $291.85M | $297.18M |
| Revenue growth (YoY) | +36.4% | -0.3% | +43.7% | +11.6% |
| Gross margin | 75.1% | n/a | n/a | 66.3% |
| Operating margin | 11.2% | -45.1% | 8.5% | -11.0% |
| Net margin | -1.9% | -30.8% | 0.2% | -17.4% |
| Net income | -$5.14M | -$80.80M | $554.0K | -$51.64M |
| EPS (Diluted) | -$0.14 | -$1.14 | $0.00 | -$0.80 |
| Operating cash flow | $43.86M | -$273.80M | $28.63M | -$42.27M |
| Free cash flow | $42.98M | -$275.70M | n/a | -$45.71M |
| Cash & equivalents | $72.93M | $142.90M | $111.04M | $53.83M |
| Total assets | $399.48M | $717.90M | $383.53M | $225.87M |
| Total liabilities | $347.39M | $284.00M | $369.84M | $248.97M |
| Shareholders' equity | $52.45M | $433.90M | $13.69M | -$23.11M |
| Return on year-end equity | -9.8% | -18.6% | 4.0% | n/a |
| Shares outstanding | 37.23M | 63.50M | 166.22M | 65.01M |
Revenue, most recent five fiscal years
| Fiscal year | Harrow, Inc. | Arvinas, Inc. | Xeris Biopharma Holdings, Inc. | Evolus, Inc. |
|---|---|---|---|---|
| Latest | $272.30M Ended 2025-12-31 | $262.60M Ended 2025-12-31 | $291.85M Ended 2025-12-31 | $297.18M Ended 2025-12-31 |
| 1 year earlier | $199.61M Ended 2024-12-31 | $263.40M Ended 2024-12-31 | $203.07M Ended 2024-12-31 | $266.27M Ended 2024-12-31 |
| 2 years earlier | $130.19M Ended 2023-12-31 | $78.50M Ended 2023-12-31 | $163.91M Ended 2023-12-31 | $202.09M Ended 2023-12-31 |
| 3 years earlier | $88.59M Ended 2022-12-31 | $131.40M Ended 2022-12-31 | $110.25M Ended 2022-12-31 | $148.62M Ended 2022-12-31 |
| 4 years earlier | $72.48M Ended 2021-12-31 | $53.60M Ended 2021-12-31 | $49.59M Ended 2021-12-31 | $99.67M Ended 2021-12-31 |